Key Points
- CEO insider buying: Amir Heshmatpour purchased 37,000 Neonc Technologies shares at an average of $3.67, investing $135,790 and increasing his direct ownership by 1.2% to 3.133 million shares.
- Stock and earnings performance: NTHI opened at $3.78, below its 50-day and 200-day moving averages, and has traded between $3.01 and $12.99 over the past year. The company reported a quarterly loss of $0.58 per share, missing the $0.12 consensus loss estimate.
- Analyst outlook is mixed: Three analysts rate the stock Buy, one rates it Hold, and one rates it Sell, producing a consensus Hold rating and an average price target of $16.00.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Amir Heshmatpour bought 37,000 shares of Neonc Technologies stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $3.67 per share, with a total value of $135,790.00. Following the completion of the purchase, the chief executive officer directly owned 3,133,000 shares in the company, valued at $11,498,110. This trade represents a 1.20% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Neonc Technologies Stock Performance
NASDAQ NTHI opened at $3.78 on Tuesday. The company has a 50-day moving average price of $4.06 and a two-hundred day moving average price of $5.32. Neonc Technologies Holdings, Inc. has a 52 week low of $3.01 and a 52 week high of $12.99.
Neonc Technologies (NASDAQ:NTHI - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. Maxim Group started coverage on Neonc Technologies in a research note on Monday, May 18th. They issued a "buy" rating and a $20.00 price target for the company. BTIG Research restated a "buy" rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, September 8th. Weiss Ratings raised shares of Neonc Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 31st. Alliance Global Partners initiated coverage on shares of Neonc Technologies in a research report on Tuesday, May 19th. They issued a "buy" rating and a $13.00 target price for the company. Finally, Wall Street Zen cut shares of Neonc Technologies from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $16.00.
View Our Latest Stock Report on Neonc Technologies
Hedge Funds Weigh In On Neonc Technologies
Hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company's stock worth $1,650,000 after buying an additional 11,108 shares in the last quarter. Westmount Partners LLC lifted its holdings in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock valued at $893,000 after buying an additional 153,858 shares during the period. BlackRock Inc. bought a new position in Neonc Technologies during the second quarter valued at about $815,000. Finally, Global Retirement Partners LLC bought a new position in Neonc Technologies during the second quarter valued at about $126,000.
About Neonc Technologies
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
